MedTrace Logo

Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer

NCT07500129 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-30

No results posted yet for this study

Summary

This prospective observational study aims to evaluate whether exosomal microRNA profiles derived from tumor tissue and blood serum are associated with pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with breast cancer.

Breast cancer patients with similar clinical and pathological features may respond differently to treatment, underscoring the need for reliable biomarkers that can help predict therapeutic outcomes. Exosomes are small extracellular vesicles released by tumor cells that carry molecular signals, including microRNAs, which may reflect tumor behavior and treatment sensitivity.

In this study, patients with breast cancer receiving standard NAC as part of routine clinical care will be followed prospectively. Exosomal microRNA profiles obtained from tumor tissue and blood samples collected during routine diagnostic and treatment procedures will be analyzed and compared with pathological complete response (pCR) assessed after completion of neoadjuvant chemotherapy.

A group of patients with benign breast disease will be included as a reference control for comparative analyses.

The results of this study may contribute to the identification of minimally invasive biomarkers that support personalized treatment strategies in breast cancer.

Conditions

  • Breast Cancer
  • Invasive Breast Carcinoma
  • Exosomal microRNA
  • Neoadjuvant Chemotherapy Response
  • Pathological Complete Response

Sponsors & Collaborators

  • Atlas University

    lead OTHER

Principal Investigators

  • EMİNE YILDIRIM · Atlas University Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-12
Primary Completion
2027-01-15
Completion
2027-04-22

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07500129 on ClinicalTrials.gov